PRESS RELEASE published on 02/10/2026 at 07:30, 5 months 26 days ago Inside Information / Other news releases 15-20 National Hospital and GenSight Biologics treat first patient in GS010/LUMEVOQ® REVISE Study, for Leber Hereditary Optic Neuropathy. Clinical study supported by ANSM and aiming to enroll 14 patients in France GenSight Biologics LHON GS010/LUMEVOQ REVISE Study 15-20 National Hospital
BRIEF published on 01/29/2026 at 00:26, 6 months 10 days ago GenSight Biologics publie les résultats de l'EGM Assemblée Générale Extraordinaire Actionnaires Augmentation De Capital GenSight Biologics Autorisations Financières
BRIEF published on 01/29/2026 at 00:26, 6 months 10 days ago GenSight Biologics Reports EGM Results Shareholders Capital Increase Extraordinary General Meeting GenSight Biologics Financial Authorizations
PRESS RELEASE published on 01/29/2026 at 00:21, 6 months 10 days ago Inside Information / Other news releases GenSight Biologics announces successful Extraordinary General Meeting approving financial authorizations renewal and clarifying rejection of 8th resolution, enhancing company's strategic flexibility Strategy Extraordinary General Meeting GenSight Biologics Gene Therapies Financial Authorizations
BRIEF published on 12/29/2025 at 08:05, 7 months 10 days ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
BRIEF published on 12/29/2025 at 08:05, 7 months 10 days ago GenSight Biologics finalise une levée de fonds de 2,9 millions d'euros. Actionnaires Thérapie Génique Collecte De Fonds Maladies De La Rétine Usage Compassionnel
PRESS RELEASE published on 12/29/2025 at 08:00, 7 months 10 days ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
PRESS RELEASE published on 12/29/2025 at 08:00, 7 months 10 days ago Informations privilégiées / Autres communiqués GenSight Biologics réalise une levée de fonds de près de €2,9 millions d’euros pour développer des thérapies géniques innovantes. La société vise le traitement des maladies neurodégénératives de la rétine Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives Rétine
BRIEF published on 12/22/2025 at 07:05, 7 months 17 days ago Délivrance d'une autorisation d'accès compassionnel pour GS010/LUMEVOQ® Thérapie Génique GenSight Biologics NOHL Accès Compassionnel ANSM
BRIEF published on 12/22/2025 at 07:05, 7 months 17 days ago GenSight Biologics obtient une autorisation d'usage compassionnel pour GS010/LUMEVOQ® en France Thérapie Génique Maladies Rares Usage Compassionnel Traitement De La LHON Approbation ANSM
Published on 08/07/2026 at 23:15, 19 hours 41 minutes ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 19 hours 56 minutes ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 20 hours 26 minutes ago UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 20 hours 41 minutes ago Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services
Published on 08/08/2026 at 16:25, 2 hours 30 minutes ago Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 19 hours 34 minutes ago EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 23 hours 25 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 23 hours 41 minutes ago ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 1 day ago Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:54, 1 day ago Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 day ago Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 1 day ago Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 1 day ago Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 1 day ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026
